For decades, women with Fabry disease were told they were simply carriers of a condition that only seriously affected men. That framing was wrong. Research now confirms that the majority of women with a Fabry gene mutation develop significant, sometimes severe symptoms. Many spend years being dismissed, misdiagnosed, or told their pain is not real. This article explains what Fabry disease looks like in women, why it is so frequently missed, and what diagnosis and treatment actually involve.

Do Women Get Fabry Disease?

Yes. Women with a mutation in the GLA gene can develop Fabry disease and experience serious symptoms affecting the kidneys, heart, nervous system, and other organs. Research confirms that 70 to 80 per cent of women with a GLA mutation develop clinically significant symptoms. Women with Fabry disease are patients, not carriers.

Fabry disease is caused by a mutation in the GLA gene, which sits on the X chromosome. Because women have two X chromosomes, one working copy of the gene was historically assumed to compensate for the mutated one. This assumption led to women being labelled carriers, a term that implied they did not have the disease themselves but could pass it to their children.

That framing is medically inaccurate. A process called lyonisation means each cell in a woman's body randomly switches off one of its two X chromosomes. In organs where the mutated X chromosome happens to be active across a significant number of cells, GL-3 accumulates and damage occurs, sometimes just as severely as in men.

The historical dismissal of women with Fabry disease as carriers has had serious consequences. Women have been denied treatment, excluded from clinical trials, and spent years in pain without answers. This article does not use the word carrier to describe women with Fabry disease, because it is both medically inaccurate and harmful.

Why Fabry Disease Presents Differently in Women?

Because of lyonisation, the random inactivation of one X chromosome per cell, women with Fabry disease can experience a much wider range of symptom severity than men. Some women develop symptoms indistinguishable from classic Fabry disease. Others develop milder but still significant involvement of specific organs. The unpredictability is itself one of the defining features of Fabry disease in women.

In men with Fabry disease, the absence of a working GLA gene copy means enzyme deficiency is consistent across the body. In women, the picture is more variable. A woman may have significant kidney involvement but minimal pain. Another may have severe neuropathic pain but normal kidney function for years. This variability made it easier for clinicians to dismiss female patients as having something other than Fabry disease.

Symptoms in women also tend to appear later on average than in men with classic Fabry, often in the teens or twenties rather than childhood. This further delayed diagnosis in an era when Fabry was considered a childhood or male disease.

Symptoms of Fabry Disease in Women

Women with Fabry disease can experience the full range of Fabry symptoms, including neuropathic pain, heat intolerance, gastrointestinal problems, kidney disease, cardiac involvement, and fatigue. These symptoms may appear later and be less predictable than in men, but they are real and they are serious.

1. Neuropathic Pain

Burning, stabbing pain in the hands and feet is one of the most common and distressing symptoms in women with Fabry disease. It is frequently dismissed as anxiety, fibromyalgia, or Raynaud's phenomenon. The pain is caused by GL-3 accumulation damaging the small nerve fibres in the hands and feet. It is not imagined. It is measurable on nerve conduction studies in many patients.

2. Heat and Exercise Intolerance

Many women with Fabry disease struggle to sweat normally, which makes regulating body temperature difficult. Heat, exercise, and warm environments can trigger severe pain episodes. Women with Fabry disease may have avoided sports, outdoor activities, or warm workplaces for years without knowing why.

3. Fatigue

Profound fatigue that is disproportionate to visible illness is one of the most consistently reported symptoms in women with Fabry disease. It is frequently attributed to depression or anxiety before a Fabry diagnosis is considered.

4. Gastrointestinal Symptoms

Abdominal pain, cramping, diarrhoea, and nausea are common, particularly after eating. These symptoms are frequently misdiagnosed as irritable bowel syndrome. Women with Fabry disease often modify their diet and daily routine around unpredictable gastrointestinal episodes for years before receiving a correct diagnosis.

5. Kidney and Cardiac Involvement

Progressive kidney disease and cardiac thickening (left ventricular hypertrophy) can occur in women with Fabry disease, sometimes as the primary or only presentation. Women should receive regular kidney function monitoring and cardiac screening after a Fabry diagnosis, regardless of whether they currently have symptoms in those organs.

6. Stroke

Women with Fabry disease are at elevated risk of stroke, including at young ages. If you or a family member has experienced a stroke with no clear cause at a young age, Fabry disease is worth investigating, particularly if there is a family history.

Why Fabry Disease in Women Is So Often Missed

Fabry disease in women is frequently missed because of three compounding factors: historical framing of Fabry as a male-only condition, symptom overlap with more common diagnoses, and the variable nature of female presentation, making it harder to match against textbook descriptions.

The average time from first symptom to Fabry diagnosis is 10 to 16 years for the general Fabry population, and many studies suggest the delay is even longer for women. There are several reasons for this.

First, Fabry disease was classified in older medical literature as an X-linked recessive condition, a framing that implied women were unaffected. Many clinicians trained on this older literature still approach Fabry disease as primarily a male condition.

Second, the symptoms of Fabry disease in women overlap significantly with conditions far more commonly diagnosed in women: fibromyalgia, lupus, multiple sclerosis, irritable bowel syndrome, anxiety, and chronic fatigue syndrome. Each symptom, treated in isolation, points away from a rare genetic disease.

Third, women with Fabry disease often retain some residual enzyme activity, which means standard enzyme assay tests can return a normal or borderline result. Enzyme assays alone are not sufficient to diagnose or exclude Fabry disease in women. Genetic testing is required.

How Fabry Disease Is Diagnosed in Women

In women, Fabry disease must be diagnosed through genetic testing for GLA mutations. Enzyme assay tests, which are reliable in men, can return normal results in women with Fabry disease and cannot be used alone to confirm or rule out the condition.

If a woman has symptoms consistent with Fabry disease, or if a family member has been diagnosed, the correct diagnostic path is genetic testing for GLA mutations. A blood or saliva sample is sent to a specialist genetic laboratory. Results typically take several weeks.

A metabolic specialist, clinical geneticist, or physician with experience in lysosomal storage disorders should interpret the results. A positive result confirming a GLA mutation should be followed by baseline organ assessments: kidney function, cardiac imaging, neurological evaluation, and ophthalmology review.

Treatment for Women With Fabry Disease

Women with Fabry disease are eligible for the same treatments as men: enzyme replacement therapy (ERT) delivered by infusion, and migalastat (Galafold) for those with amenable mutations. Treatment decisions should be based on symptoms, organ involvement, and mutation type, not on assumptions about severity in women.

Enzyme replacement therapy provides the body with a manufactured version of the missing alpha-Gal A enzyme, delivered intravenously every two weeks. Migalastat is an oral tablet taken every other day and is suitable for patients with specific GLA mutations. A treating specialist will determine which option is appropriate based on your mutation and clinical picture.

Monitoring is equally important. Regular kidney function tests, cardiac imaging, and neurological assessments help catch disease progression early. Women with Fabry disease should have a treating team that includes a nephrologist, cardiologist, and neurologist with rare disease experience.